Orthocell announces new agreement with US-based BioHorizons

Latest News

Regenerative medicine company Orthocell (ASX:OCC) has entered into an exclusive patent and trademark license agreement and an exclusive distribution and supply agreement with BioHorizons Implant Systems.

Under the agreements, Orthocell will grant the US-based company an exclusive licence to two patent families covering a collagen scaffold for cell growth and a method for producing a collagen membrane, associated patent applications, improvements and know-how and the Striate+ trademark.

The licence relates to the Striate+ products for dental and oral-maxillofacial procedures. The term of the licence is linked to the term of the supply and distribution agreement (25 years).

Under the terms of the agreement, BioHorizons will pay Orthocell $23.1 million (USD $16 million) within two business days of the date of execution.

BioHorizons president and CEO Steve Boggan said, “We are very pleased to partner with Orthocell to offer our valued customers a dental membrane with excellent handling properties and regenerative potential. Striate+ will be a highly complementary addition to our global biomaterials product portfolio for dental tissue regeneration.”

Orthocell managing director Paul Anderson said, “BioHorizons is a leading global provider of dental implant and tissue regenerative products with specialist capabilities and res to expand the marketing, promotion and supply of Striate+ worldwide. We are delighted to be working with BioHorizons which has established relationships with dentists and dental specialists and a successful track record in driving the market entry of high-quality products.

“The Agreements with BioHorizons represent a significant milestone for Orthocell and provide further external commercial and technical validation of the CelGro collagen scaffold platform, from which the Striate+™ dental products were developed.”

Striate+ is a resorbable collagen membrane used in guided bone and tissue regeneration procedures.

BioHorizons will market and distribute Striate+ alongside its innovative and evidence-based dental implants and tissue regeneration products.